BioAge Labs, Inc. Common Stock
Veridion Score
Composite trend over time
Why is BIOA moving today?
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BIOA.
BIOA insider activity
BioAge Labs, Inc. Common Stock
2 insiders bought in the last 90 days
Net selling: -$6.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Barton Shane | Insider | sell | $25.19 | 20,216 | Not reported | $509K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | Barton Shane | Insider | buy | $4.38 | 7,861 | 20,216 | $34K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | Barton Shane | Insider | buy | $4.30 | 4,065 | 12,355 | $17K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | Barton Shane | Insider | buy | $8.39 | 4,000 | 8,290 | $34K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | Barton Shane | Insider | buy | $10.85 | 4,290 | 4,290 | $47K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 31 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBIOA contract awards, year to date.
Public federal awards linked to this ticker.
BIOA lobbying filings, year to date.
Registered lobbying filings matched to BioAge Labs, Inc. Common Stock.